跳至主要内容
临床试验/CTRI/2010/091/000159
CTRI/2010/091/000159招募中未知

"Safety and efficacy of liposomal amphotericin B (Ambisome) in patients with post kala-azar dermal leishmaniasis(PKDL)".

RMRIMS(ICMR).0 个研究点目标入组 50 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • ?Male or female patient aged 5 years or older
  • ?Post kala azar dermal leishmaniasis (PKDL), parasitologically confirmed (amastigotes in slit-skin or snip skin smears and/or skin biopsies)
  • ?Nodules, papules or plaques as clinical signs consistent with post kala azar dermal leishmaniasis.

排除标准

  • Safety concerns:
  • ?Thrombocyte count <100 x 109/l
  • ?Leukocyte count <1.5 x 109/l
  • ?Hemoglobin < 5.0 g/100 ml
  • ?ASAT, ALAT, AP >3 times upper limit of normal range
  • ?Bilirubin >2 times upper limit of normal range
  • ?Serum creatinine or BUN >1.5 times upper limit of normal range
  • ?Major surgery within last 2 weeks
  • ?Any non-compensated or uncontrolled condition, such as active tuberculosis, malignant disease, severe malaria, HIV, or other major infectious diseases
  • Lack of suitability for the trial:
  • ?Concomitant treatment with other anti-leishmaniasis drugs

研究者

发起方
RMRIMS(ICMR).

相似试验